What is the price-to-earnings ratio of Biontech?
The price-earnings ratio of Biontech is currently -39.19.
Biontech P/E 2024
Biontech P/E
-39.19
Ticker
BNTX
ISIN
US09075V1026
WKN
A2PSR2
As of Sep 12, 2024, Biontech's P/E ratio was -39.19, a -255.27% change from the 25.24 P/E ratio recorded in the previous year.
The Biontech P/E history
Biontech Aktienanalyse
What does Biontech do?
BioNTech SE is a German biotech company specializing in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2008 by Ugur Sahin and Özlem Türeci and is headquartered in Mainz. History: BioNTech was established to develop novel treatment options for cancer patients. Originally started as a pure research company, the company has since evolved into a global leader in mRNA-based therapeutics. In recent years, BioNTech has entered into numerous collaborations and partnerships with renowned pharmaceutical companies and other research institutions to strengthen its innovative power and competitiveness. Business model: BioNTech's business model involves developing novel mRNA-based therapeutics for the treatment of cancer and other serious diseases. The company relies on close collaboration with other research institutions and pharmaceutical companies to leverage the latest scientific knowledge and technologies. BioNTech aims to bring its therapeutics to market as quickly as possible to enable more effective treatment for patients worldwide. Divisions: BioNTech is divided into various divisions to optimize its research activities. One of the most important divisions is cancer research, in which the company specifically seeks new treatment options for various types of cancer. BioNTech focuses on the development of personalized cancer immunotherapy tailored to the individual needs of each patient. In this context, the company works closely with other researchers and oncologists to achieve the best possible outcomes. Another important area of BioNTech is vaccine development. The company uses mRNA technology to rapidly and effectively develop vaccines against various infectious diseases. In 2020, BioNTech, together with the US pharmaceutical company Pfizer, brought the first mRNA vaccine against COVID-19 to the market, which has high efficacy and safety. This technology enables rapid response to new pathogens and targeted vaccine development. Products: BioNTech offers a variety of therapeutics and vaccines based on mRNA technology. One of the company's most important products is the mRNA vaccine against COVID-19, which is in use worldwide. In addition, BioNTech develops personalized cancer immunotherapies tailored to the individual characteristics of patients' tumors. Another product of BioNTech is mRNA immunotherapies that can be used for various autoimmune diseases. Conclusion: BioNTech is an innovative biotech company specializing in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. With its business model that relies on collaborations and partnerships, the company is able to rapidly and effectively respond to new challenges while staying scientifically up to date. BioNTech has brought a variety of products to the market in a short period of time that have high efficacy and safety, thereby helping patients worldwide. Answer: BioNTech is a German biotech company that specializes in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. Biontech ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Biontech's P/E Ratio
The Price to Earnings (P/E) Ratio of Biontech is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Biontech's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Biontech is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Biontech’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Biontech stock
How has the price-earnings ratio of Biontech changed compared to last year?
The price-to-earnings ratio of Biontech has increased by -255.27% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Biontech high compared to other companies?
Yes, the price-to-earnings ratio of Biontech is high compared to other companies.
How does an increase in the price-earnings ratio of Biontech affect the company?
An increase in the price-earnings ratio of Biontech would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Biontech affect the company?
A decrease in the price-earnings ratio of Biontech would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Biontech?
Some factors that influence the price-earnings ratio of Biontech are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Biontech pay?
Over the past 12 months, Biontech paid a dividend of 2.13 EUR . This corresponds to a dividend yield of about 2.37 %. For the coming 12 months, Biontech is expected to pay a dividend of 0 EUR.
What is the dividend yield of Biontech?
The current dividend yield of Biontech is 2.37 %.
When does Biontech pay dividends?
Biontech pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biontech?
Biontech paid dividends every year for the past 2 years.
What is the dividend of Biontech?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biontech located?
Biontech is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biontech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biontech from 6/17/2022 amounting to 2.132 EUR, you needed to have the stock in your portfolio before the ex-date on 6/2/2022.
When did Biontech pay the last dividend?
The last dividend was paid out on 6/17/2022.
What was the dividend of Biontech in the year 2023?
In the year 2023, Biontech distributed 2.132 EUR as dividends.
In which currency does Biontech pay out the dividend?
The dividends of Biontech are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Biontech stock can be added to a savings plan with the following providers: Scalable Capital and Consorsbank
Andere Kennzahlen von Biontech
Our stock analysis for Biontech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biontech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
